New York, NYNCT07572825Now EnrollingIRB Ready

DHDDS-Congenital Disorder of Glycosylation Clinical Trial in New York, NY

Access cutting-edge dhdds-congenital disorder of glycosylation treatment through this phase 1 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Eva Morava-Kozicz

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access dhdds-congenital disorder of glycosylation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related dhdds-congenital disorder of glycosylation treatment provided free

Apply for This New York Location

Check if you qualify for this dhdds-congenital disorder of glycosylation clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This DHDDS-Congenital Disorder of Glycosylation Study in New York

The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.

Sponsor: Eva Morava-Kozicz

Who Can Participate

Inclusion Criteria

Subject is ≥ 4 years old
Subject has biologically and genetically proven heterozygous DHDDS-CDG.
Subject/legally authorized representative (LAR) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study.

Exclusion Criteria

Subject has intellectual disability with IQ\<52 (moderate or lower IQ intellectual disability).
In the site Principal Investigator's opinion, subject has a history of intolerance to NMN or other niacin metabolite supplement that precludes the subject from participation in this study.
Subject has any of the following:
Liver failure
ALT level \>5x ULN
AST level \>5x ULN
eGFR \< 30 OR creatinine \>180 mmol/L
Subject is pregnant.
Use of investigational compounds within the previous 6 months or current enrollment in another trial involving investigational compounds.
Concomitant use of the following medications that could interact with orally administered NMN:
Statins or other cholesterol-lowering drugs
In the site Principal Investigator's opinion, subject is not able or willing to comply with the trial requirements.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07572825) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

DHDDS-Congenital Disorder of Glycosylation Treatment Options in New York, NY

If you're searching for dhdds-congenital disorder of glycosylation treatment options in New York, NY, this clinical trial (NCT07572825) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced dhdds-congenital disorder of glycosylation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all dhdds-congenital disorder of glycosylation clinical trials near you to find additional studies recruiting in your area.

More Huntingtons Disease Trials in New York, NY

See all huntingtons disease clinical trials recruiting in New York — not just this study.

Browse Huntingtons Disease Trials in New York →

Browse More Trials by Condition

Huntingtons Disease TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY